TY  - JOUR
PY  - 2021//
TI  - Novel psychopharmacology for depressive disorders
JO  - Advances in experimental medicine and biology
A1  - Fornaro, Michele
A1  - De Berardis, Domenico
A1  - Anastasia, Annalisa
A1  - Fusco, Andrea
SP  - 449
EP  - 461
VL  - 1305
IS  - 
N2  - Major depressive disorder carries a significant burden and a high risk for suicide. The need for more effective, safer, and faster-acting drugs is, therefore, compelling. The present chapter briefly assesses the most promising agents, focusing on non-monoamine-targeting compounds, namely, the glutamate antagonist ketamine and its enantiomer esketamine. A critical overview of the evidence and the pitfalls associated with current antidepressant drug development is likewise provided in the following text.<p />  <p>Language: en</p>
LA  - en
SN  - 0065-2598
UR  - http://dx.doi.org/10.1007/978-981-33-6044-0_22
ID  - ref1
ER  -